Longeveron announced publication of Phase 1 safety, tolerability and efficacy data of its proprietary allogeneic mesenchymal stem cell (MSC) product in patients with Aging Frailty. The results were published on April 21st online in the Journals of Gerontology.

According to the senior author, Samuel Golpanian, M.D., of the Department of Surgery at the University of Miami's Miller School of Medicine/Jackson Memorial Hospital, "This study is ground-breaking, not only by demonstrating that MSC treatment in this patient population is safe, but the treatment has led to improvements in functional and immunologic status."

Aging Frailty is a common geriatric syndrome characterized by impaired strength, mobility and endurance, and increased weight loss and fatigue, leading to overall decline, loss of independence and mortality. This serious and life threatening condition currently has no FDA-approved therapy, and Longeveron is leading the effort to develop a safe and effective treatment for this unmet medical need.

Longeveron, building on its Phase 1 and Phase 2 trial results, will initiate a multicenter, randomized Phase 2b clinical trial of three different doses of its proprietary allogeneic MSCs compared to placebo in Aging Frailty subjects this month.  Longeveron has exclusively licensed data from the Phase 1 and Phase 2 trials completed at the University of Miami's Miller School of Medicine.